NovoCure Limited
NASDAQ:NVCRMedical - Instruments & Supplies
-$3.51 today
- Market cap
- $1.25B
- Beta
- 0.92
- P/E (TTM)
- -9.5
- EPS (TTM)
- -$1.52
Volume 1.41M
Average 1.52M
NVCR Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
NovoCure LimitedNASDAQ: NVCR
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $174.06M rose 12.3% year over year, ahead of the +8.5% change in trailing-twelve-month revenue. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $740.8M (+13.0%) for the fiscal year ending Dec 2026, a step up from the +8.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $174.06M-0.2% QoQ
- Last fiscal yearDec 2025
- $655.35M+8.3% YoY
- LTMMar 2026
- $674.41M+8.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.3% | +8.6% | -3.7 pp |
| 1 year | +8.3% | +13.0% | +4.8 pp |
| 3-year CAGR | +6.8% | +10.8% | +4.0 pp |
| 5-year CAGR | +21.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 655.35M USD
- Year-over-year change
- +8.3%
- 4-year CAGR
- +5.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 655.35M | +8.3% |
| FY2024 | 2024-12-31 | 605.22M | +18.8% |
| FY2023 | 2023-12-31 | 509.34M | -5.3% |
| FY2022 | 2022-12-31 | 537.84M | +0.5% |
| FY2021 | 2021-12-31 | 535.03M | — |
Revenue vs competitors
How NVCR compares with its peers on the latest reported figures
- NVCR's LTM Mar 2026 revenue of $674.41M is the highest of the 4 companies compared; the peer median is $90.44M.
- Its year-over-year change of +8.5% is the lowest of 3, against a peer median of +43.0%.
- Over three fiscal years its annual growth of +6.8% compares with a peer median of +30.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $674.41M | +8.5% | +6.8% | |
| LTM Mar 2026 | $99.53M | +18.1% | +30.0% | |
| LTM Mar 2026 | $90.44M | +67.9% | +215.3% | |
| LTM Jun 2026 | $1.19M | — | -20.6% | |
| Peer median (excluding NVCR) | $90.44M | +43.0% | +30.0% | |
Competitors are the stored peer set for NVCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 535.03M | 537.84M | 509.34M | 605.22M | 655.35M |
| Cost of Revenue | 114.88M | 114.87M | 128.28M | 137.18M | 166.88M |
| Gross Profit | 420.15M | 422.97M | 381.06M | 468.04M | 488.47M |
| Gross Margin | 78.5% | 78.6% | 74.8% | 77.3% | 74.5% |
| Research & Development | 201.3M | 206.09M | 223.06M | 209.65M | 224.54M |
| Selling, General & Admin | 263.18M | 306.41M | 390.87M | 428.89M | 417.73M |
| Operating Expenses | 464.49M | 512.5M | 614.67M | 638.54M | 642.27M |
| Depreciation & Amortization | 10.25M | 10.62M | 10.97M | 11.24M | 17.2M |
| EBITDA | (38.38M) | (67.89M) | (177.45M) | (109.58M) | (119.05M) |
| EBITDA Margin | -7.2% | -12.6% | -34.8% | -18.1% | -18.2% |
| Operating Income | (44.33M) | (89.52M) | (232.87M) | (170.5M) | (153.8M) |
| Operating Margin | -8.3% | -16.6% | -45.7% | -28.2% | -23.5% |
| Interest Income | 1.1M | 15.79M | 46.04M | 51M | 18.11M |
| Interest Expense | 8.84M | 8.11M | 4.91M | 11.66M | 0 |
| Other Income / Expenses | (7.74M) | 7.68M | 41.13M | 39.33M | 17.55M |
| Income Before Tax | (52.08M) | (81.85M) | (191.74M) | (131.16M) | (136.25M) |
| Pre-Tax Margin | -9.7% | -15.2% | -37.6% | -21.7% | -20.8% |
| Income Tax Expense | 6.28M | 10.69M | 15.3M | 37.47M | (23K) |
| Net Income | (58.35M) | (92.53M) | (207.04M) | (168.63M) | (136.23M) |
| Net Margin | -10.9% | -17.2% | -40.6% | -27.9% | -20.8% |
| EPS (Basic) | (0.56) | (0.88) | (1.95) | (1.56) | (1.22) |
| EPS (Diluted) | (0.56) | (0.88) | (1.95) | (1.56) | (1.22) |
| Weighted Avg Shares | 103.43M | 104.66M | 106.39M | 107.83M | 111.47M |
| Weighted Avg Shares (Diluted) | 103.43M | 104.66M | 106.39M | 107.83M | 111.47M |
NovoCure Limited
NASDAQ:NVCR
Intrinsic Alpha fair value
Locked
Current Price
$10.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.